

Bioactive 5,6-Dihydro- α -pyrone Derivatives from *Hyptis brevipes*

Ye Deng,[†] Marcy J. Balunas,^{†,‡} Jeong-Ah Kim,[§] Daniel D. Lantvit,[‡] Young-Won Chin,[†] Heebyung Chai,[†] Sugeng Sugiarto,[⊥] Leonardus B. S. Kardono,^{||} Harry H. S. Fong,[‡] John M. Pezzuto,^{‡,▽} Steven M. Swanson,[‡] Esperanza J. Carcache de Blanco,^{†,§} and A. Douglas Kinghorn^{*†}

Division of Medicinal Chemistry and Pharmacognosy and Division of Pharmacy Practice and Administration, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, Program for Collaborative Research in the Pharmaceutical Sciences and Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, Research Center for Indonesian Medicinal Plants, Ministry of Health, Tawangmangu 57792, Indonesia, and Research Center for Chemistry, Indonesian Institute of Science, Tangerang 15310, Indonesia

Received March 16, 2009

Six new 5,6-dihydro- α -pyrone derivatives (**1–6**), namely, brevipolides A–F, together with seven known compounds, including a 5,6-dihydro- α -pyrone derivative (**7**), three flavonoids, a steroid glycoside, and two triterpenoids, were isolated from the entire plant of *Hyptis brevipes*. Compounds **1–7** were assigned with the absolute configuration 5*R*, 6*S*, 7*S*, and 9*S*, as elucidated by analysis of data obtained from their CD spectra and by Mosher ester reactions. Compounds **2**, **6**, and **7** exhibited ED₅₀ values of 6.1, 6.7, and 3.6 μ M against MCF-7 cells, and compounds **1**, **2**, **6**, and **8** (the known 5,6,3'-trihydroxy-3,7,4'-trimethoxyflavone) gave ED₅₀ values of 5.8, 6.1, 7.5, and 3.6 μ M against HT-29 cells, respectively. However, no significant cytotoxicity was found against Lu1 cells for any of the compounds isolated. When these compounds were subjected to evaluation in a panel of mechanism-based in vitro assays, compound **7** was found to be active in an enzyme-based ELISA NF- κ B assay, with an ED₅₀ value of 15.3 μ M. In a mitochondrial transmembrane potential assay, compounds **3**, **7**, and **8** showed ED₅₀ values of 8.5, 75, and 310 nM, respectively. No potent activity was found in a proteasome inhibition assay for any of the isolated compounds.

The genus *Hyptis* (Lamiaceae) is composed of approximately 350–400 species in the form of small herbs to large bushes, which are distributed in the tropics and warmer temperate regions all over the world. Previous studies on the constituents of species of the genus *Hyptis* have revealed diterpenoids,^{1,2} flavonoids,^{3,4} lignans,^{4,5} and α -pyrone derivatives.^{6,7} *Hyptis brevipes* Plot. originated from tropical America but is now widely distributed in other tropical regions of the world as an alien invasive species. Biological studies on crude extracts of this plant have shown inhibitory activities against bacterial and fungal growth, as well as DNA intercalation activity.^{8,9} There has been no previous report on the phytochemical evaluation of this plant to date.

As part of a collaborative, multidisciplinary approach to the discovery of new naturally occurring anticancer drugs,^{10,11} the entire plant of *H. brevipes* was selected for further investigation, following initial cytotoxicity screening using the MCF-7 human breast cancer cell line. Cytotoxicity assay-guided fractionation and purification of the chloroform-soluble extract of *H. brevipes* led to the isolation and biological evaluation of six new (**1–6**) and one known (**7**) 5,6-dihydro- α -pyrone derivatives, as well as three known flavonoids, a steroid glycoside, and two triterpenoids. Compounds **1–6**, bearing a cyclopropane moiety, belong to a novel skeletal class that was first reported in 2004, when **7** and several analogues were found to be chemokine receptor 5 (CCR5) inhibitors.¹² The structures of the other known compounds isolated in the present study were identified by

physical and spectroscopic measurements ($[\alpha]_D$, ¹H NMR, ¹³C NMR, DEPT, 2D-NMR, and MS) and by comparing the data obtained with published values, as daucosterol,¹³ ursolic acid,¹⁴ 2 α -hydroxyursolic acid (maslinic acid),¹⁴ 5,3'-dihydroxy-3,7,4'-trimethoxyflavone (ayanin),¹⁵ 3,5,3'-trihydroxy-7,4'-dimethoxyflavone (ombuin),¹⁶ and 5,6,3'-trihydroxy-3,7,4'-trimethoxyflavone (**8**).¹⁷

The development of cancer involves a wide spectrum of changes at the molecular level, which include, but are not limited to, sustained activation of proteasome and nuclear factor κ B (NF- κ B), as well as resistance to apoptosis. Proteasomes present in the cytoplasm and nucleus of eukaryotic cells serve a key role in regulating cell cycle progression, signal transduction, transcription regulation, and apoptosis. Proteasome inhibition has been demonstrated as a relatively new approach to treating cancer.^{18,19} NF- κ B is a tightly regulated transcription factor that is maintained in an inactive form under most basal conditions. Previous studies have shown that constitutively activated NF- κ B is associated with many spontaneous and virally induced oncogenesis events in humans, leading to cancer cell proliferation and survival, as well as being related to angiogenesis and metastasis. Therefore, chemotherapy targeting the NF- κ B signal transduction pathway has been proposed for anticancer drug development.^{20–22} One of the most important mechanisms for cancer cell survival is evasion from apoptosis, and chemical agents that can induce programmed cell death may be effective against many types of cancers.^{23,24} During apoptosis, several key events occur in the mitochondria, including the loss of mitochondrial transmembrane potential ($\Delta\Psi_m$). Thus, $\Delta\Psi_m$ measurement can be used as an indicator of cellular health.²⁵ Accordingly, the extracts, chromatographic fractions, and pure isolates from *H. brevipes* were subjected to testing in the MCF-7 cytotoxicity assay, as well as in proteasome inhibition, NF- κ B inhibition, and mitochondrial transmembrane potential assays.

* To whom correspondence should be addressed. Tel: +1-614-247-8094. Fax: +1-614-247-8081. E-mail: kinghorn.4@osu.edu.

[†] Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University.


[‡] University of Illinois at Chicago.

[§] Division of Pharmacy Practice and Administration, The Ohio State University.

[⊥] Research Center for Indonesian Medicinal Plants.

^{||} Indonesian Institute of Science.

[▽] Present address: College of Pharmacy, University of Hawaii–Hilo, Hilo, Hawaii 96720.



Results and Discussion

Compound **1** was obtained as a colorless gum and afforded a sodiated molecular ion peak at m/z 451.1354 (calcd for C₂₃H₂₄O₈Na, 451.1369) in the HRESIMS. The ¹H NMR spectroscopic data of **1** (Table 1) showed a characteristic AA'BB' system of a *para*-substituted benzene ring at δ_{H} 7.35 (2H, d, J = 8.5 Hz, H-2', H-6') and 6.83 (2H, d, J = 8.5 Hz, H-3', H-5'). Resonance signals at δ_{H} 7.62 (1H, d, J = 16.0 Hz, H-7') and 6.27 (1H, d, J = 16.0 Hz, H-8') suggested the presence of a *trans* double bond. Signals of a *cis* double bond adjacent to a methylene group were also observed at δ_{H} 6.95 (1H, ddd, J = 9.4, 6.6, 2.3 Hz, H-3), 6.05 (1H, dd, J = 9.4, 2.6 Hz, H-2), 2.65 (1H, m, H-4 β), and 2.48 (1H, m, H-4 α). In the COSY spectrum, two oxygenated methine groups were found to be connected to one another, which was substantiated by analyzing coupling constants of the resonance signals at δ_{H} 4.70 (1H, dd, J = 8.7, 3.7 Hz, H-6) and 4.61 (1H, dt, J = 12.2, 3.7 Hz, H-5). Also, using the COSY spectrum, another oxygenated methine group was determined to be connected to a methyl functionality from correlations between signals at δ_{H} 5.25 (1H, q, J = 7.0 Hz, H-11) and 1.50 (3H, d, J = 7.0 Hz, H-12). The methylene signals occurring in the upfield region at δ_{H} 1.41 (1H, m, H-8 α) and 1.08 (1H, m, H-8 β), together with signals at δ_{H} 2.33 (1H, m, H-9) and 1.69 (1H, m, H-7), were attributed to the presence of a cyclopropane ring.²⁶ A singlet signal at δ_{H} 2.14 (3H, s, OAc) suggested the presence of an acetyl group. Consistent with the ¹H NMR data, the ¹³C NMR and DEPT135 spectroscopic data of **1** also showed signals of a *para*-substituted benzene ring at δ_{C} 158.9 (C-4'), 126.1 (C-1'), 130.1 (C-2', 6'), and 116.0 (C-3', 5'), two double bonds at δ_{C} 146.0 (C-7'), 145.1 (C-3), 121.0 (C-2), and 113.6 (C-8'), three oxygenated methine carbons at δ_{C} 77.9 (C-5), 75.0 (C-11), and 74.5 (C-6), two methine carbons at δ_{C} 25.2 (C-7) and 22.5 (C-9), two methylene carbons at δ_{C} 24.3 (C-4) and 14.4 (C-8), and two methyl carbons at δ_{C} 20.9 (OAc) and 15.9 (C-12). Furthermore, four carbonyl carbon signals at δ_{C} 207.3 (C-10), 170.5 (OAc), 168.8 (C-9'), and 163.7 (C-1) could be assigned, in turn, to a ketone, an acetyl, an α,β -unsaturated ester, and an α,β -unsaturated lactone functionality. In the ¹H-¹H COSY spectrum of compound **1** (Figure 1), correlations from H-5 and H-7 to H-6 indicated the lactone and cyclopropane moieties to be connected through C-6. Other 2D NMR spectroscopic correlations observed in the HMBC experiment (Figure 1) were supportive of the proposed planar structure.

The relative configuration of compound **1** at the C-5, C-6, and C-7 positions was determined by correlations from H-7 to H-4 α ,

H-5, and H-8 α , as well as from H-6 to H-8 β and H-9, in the NOESY spectrum (Figure 2) and by comparison with the data of reported analogues.¹² The CD spectrum of compound **1** exhibited a positive Cotton effect at 259.5 nm. According to the published observations between chirality in α,β -unsaturated δ -lactones and the Cotton effect around 260 nm, the absolute configuration of compound **1** at the C-5 position could be determined as *R*.²⁷ Thus, the structure of the new compound **1** was established as depicted, and it was assigned the trivial name brevipolide A.

The HRESIMS of compound **2** provided a sodiated molecular ion peak at m/z 451.1343, corresponding to an elemental formula of C₂₃H₂₄O₈Na (calcd 451.1369), the same as that of compound **1**. In addition, the UV, CD, IR, and NMR spectra of compound **2** were found to be closely comparable to those of compound **1**, indicating that these two compounds are geometrical isomers. The coupling constant values of the resonance signals at δ_{H} 6.89 (1H, d, J = 12.7 Hz, H-7') and 5.86 (1H, d, J = 12.7 Hz, H-8') suggested that **2** is a *Z* isomer of compound **1** at the phenylpropanoid double-bond position. Accordingly, the new compound, brevipolide B (**2**), was assigned as shown.

Compound **3** (brevipolide C) was obtained as a colorless gum. Its HRESIMS exhibited a sodiated molecular ion peak at m/z 425.1216 (calcd for C₂₁H₂₂O₈Na, 425.1212). The structure of compound **3** was found to be similar to that of compound **1**. However, the ¹H NMR spectrum of **3** (Table 1) showed 1,3,4-trisubstituted aromatic proton signals at δ_{H} 7.19 (1H, br s, H-2'), 7.08 (1H, d, J = 8.2 Hz, H-6'), and 6.88 (1H, d, J = 8.2 Hz, H-5'), indicating the presence of a caffeoyl moiety. The absence of acetyl functionality signals in both the ¹H and ¹³C NMR spectra, as well as an upfield shift of the H-6 signal in the ¹H NMR spectrum to δ_{H} 3.72 in compound **3**, when compared with δ_{H} 4.70 in compound **1**, suggested the occurrence of a free hydroxy group at the C-6 position. Therefore, a planar structure could be proposed for **3**.

The absolute configuration at C-6 of compound **3** was determined using the Mosher ester procedure.²⁸⁻³¹ The chemical shift difference values [$\Delta\delta_{\text{S}} - \delta_{\text{R}}$, H-2 (+0.06), H-3 (+0.11), H-4 (+0.2), H-5 (+0.11), H-6 (+0.01), H-7 (-0.11), H-8 (-0.06 and -0.11), H-9 (-0.03), H-11 (-0.04)] obtained by comparing the relevant ¹H NMR data of the *R*- and *S*-MTPA esters of compound **3** indicated the absolute configuration of C-6 to be *S*. Hydrolysis reactions catalyzed by different acids and bases, as well as the esterase enzyme, were carried out in an attempt to produce a derivative of **3** with a free C-11 hydroxy group, so that this could be used for a Mosher ester reaction to determine the configuration of this position. However, all the hydrolysis products obtained racemized at the C-11 position, probably due to the formation of enol intermediates during the reactions.



The molecular formula of compound **4** was determined as C₂₁H₂₂O₈, from the sodiated molecular ion peak at m/z 425.1187 (calcd for C₂₁H₂₂O₈Na, 425.1212) in the HRESIMS. Its ¹H and ¹³C NMR spectra were similar to those of compound **3** except for a difference due to the double bond in the caffeoyl moiety. A *cis* double bond in compound **4** was concluded from the coupling constant values of resonance signals at δ_{H} 6.89 (1H, d, J = 12.9 Hz, H-7') and 5.85 (1H, d, J = 12.9 Hz, H-8'), compared to the value of $J_{78'} = 15.9$ Hz in the *trans* form in compound **3**. Therefore, the structure of brevipolide D was assigned as **4**.

Compound **5** was obtained as a colorless gum. The HRESIMS showed a sodiated molecular ion peak at m/z 467.1293, consistent with an elemental formula of C₂₃H₂₄O₉Na (calcd 467.1318). The ¹H and ¹³C NMR spectra of compound **5** exhibited closely related signals to those of compound **3**, but with signals of an additional acetyl group at δ_{H} 2.13 (3H, s) and δ_{C} 172.1 and 21.0. The downfield shift of the proton resonance at δ_{H} 4.77 (1H, dd, J = 8.4, 3.9 Hz, H-6), when compared with that in compound **3**,

Table 1. ^1H NMR Chemical Shifts of **1–6** (δ_{H} , mult., J in Hz)

position	1 ^a	2 ^a	3 ^b	4 ^b	5 ^c	6 ^b
2	6.05, dd, 9.4, 2.6	6.03, dd, 7.9, 1.2	5.92, dd, 9.9, 1.5	5.92, ddd, 10.8, 1.7, 1.7	5.99, d, 7.9	5.92, ddd, 9.5, 1.9, 1.9
3	6.95, ddd, 9.4, 6.6, 2.3	6.93, m	7.08 (overlapped with H-5')	7.06, ddd, 10.2, 4.5, 4.5	7.07 (overlapped with H-5')	7.05, dt, 9.5, 4.3
4	2.48, m; 2.65, m	2.39, m; 2.62, m	2.61, m (2H)	2.62, m (2H)	2.60, m (2H)	2.63, m (2H)
5	4.61, dt, 12.2, 3.7	4.59, dt, 12.2, 3.7	4.50, ddd, m	4.49, ddd, 8.0, 8.0, 4.5	4.59, dt, 10.8, 3.9	4.50, ddd, 8.0, 8.0, 4.3
6	4.70, dd, 8.7, 3.7	4.68, dd, 8.6, 3.7	3.72, t, 4.7	3.73, t, 4.5	4.77, dd, 8.4, 3.9	3.74, t, 4.3
7	1.69, m	1.68, m	1.61, m	1.62, m	1.64, m	1.61, m
8	1.08, m; 1.41, m	1.03, m; 1.41, m	1.14, m (2H)	1.15, m (2H)	1.16, m; 1.31, m	1.13, m (2H)
9	2.41, m	2.35, m	2.36, m	2.36, m	2.35, m	2.36, m
11	5.25, q, 7.0	5.16, q, 7.0	5.30, q, 7.0	5.26, q, 7.1	5.21, q, 7.1	5.28, q, 7.1
12	1.50, d, 7.0	1.43, d, 7.0	1.49, d, 7.0	1.46, d, 7.1	1.46, d, 7.1	1.46, d, 7.1
2'	7.35, d, 8.5	7.57, d, 8.2	7.19, br s	7.64, d, 1.8	7.07, br s	7.77, d, 8.5
3'	6.83, d, 8.5	6.79, d, 8.2				6.85, d, 8.5
5'	7.35, d, 8.5	7.57, d, 8.2	6.88, d, 8.2	6.82, d, 8.2	6.80, d, 8.1	7.77, d, 8.5
6'	6.83, d, 8.5	6.79, d, 8.2	7.08, d, 8.2	7.16, dd, 8.2, 1.8	6.97, dd, 8.1, 1.6	6.85, d, 8.5
7'	7.62, d, 16.0	6.89, d, 12.7	7.60, d, 15.9	6.89, d, 12.9	7.60, d, 16.0	6.97, d, 12.9
8'	6.27, d, 16.0	5.86, d, 12.7	6.36, d, 15.9	5.85, d, 12.9	6.32, d, 16.0	5.87, d, 12.9
OAc	2.14, s	2.06, s			2.13, s	

^a In CDCl_3 , ^b In acetone- d_6 , ^c In CD_3OD .

**Figure 1.** Selected ^1H – ^1H COSY (–) and HMBC (↷) correlations observed for **1**.**Figure 2.** Selected NOESY (↔) correlations observed for **1**.

suggested that this acetyl group is substituted at the C-6 hydroxy functionality. Thus, the new brevipolide E was assigned with the structure **5**.

A sodiated molecular ion peak for compound **6** was observed at m/z 409.1263 (calcd for $\text{C}_{21}\text{H}_{22}\text{O}_7\text{Na}$, 409.1263) in the HRESIMS. The ^1H and ^{13}C NMR spectra of compound **6** were closely comparable to those of compound **2**. However, the absence of acetyl functionality signals and the migration of H-6 signals from δ_{H} 4.68 of compound **2** to δ_{H} 3.74 in the ^1H NMR spectrum indicated the presence of a free hydroxy group at the C-6 position. Therefore, brevipolide F was established structurally as **6**.

On the basis of the similar CD spectroscopic profiles and NOESY NMR correlations of all the new compounds and of the known compound **7**, it could be assumed that all of these substances have the same absolute configuration. Therefore, the absolute configuration of compounds **1–7** was determined as $5R$, $6S$, $7S$, and $9S$, with the C-11 position unresolved in each case.

All the isolated compounds were evaluated for their cytotoxicity against MCF-7 human breast cancer cells, HT-29 human colon cancer cells, and Lu1 human lung cancer cells, performed according to standard protocols.³² Of these 13 isolates, compounds **2**, **6**, and **7** were found to be active principles, with ED_{50} values of 6.1, 6.7, and $3.6 \mu\text{M}$ against MCF-7 cells, and compounds **1**, **2**, **6**, and **8** with ED_{50} values of 5.8, 6.1, 7.5, and $3.6 \mu\text{M}$ against HT-29 cells, respectively. No significant activity was found against Lu1 cells for any of the compounds tested. The ED_{50} values of compounds **1** and **3–5** against MCF-7 cells were $>10 \mu\text{M}$ in each case. These

data suggest that the *cis* isomers are more cytotoxic than their *trans* counterparts for this cell line, and esterification at the C-6 position in compounds **1** and **2** as well as hydroxy substitution at the C-3' position in compounds **3** and **4** led to a decrease of activity when compared to compounds **6** and **7**. It is also apparent that hydroxy substitution at the C-3' position led to decreased cytotoxicity for these 5,6-dihydro- α -pyrones against HT-29 cells.

All compounds were subjected to evaluation in a panel of mechanism-based *in vitro* assays. However, only compounds **3**, **4**, and **8** were found to show any measurable activity at all in a proteasome inhibition assay, with ED_{50} values of 38.0, 44.5, and $17 \mu\text{M}$, respectively.^{33,34} In an enzyme-based ELISA NF- κB assay, compound **7** demonstrated an ED_{50} value of $15.3 \mu\text{M}$, compared with ED_{50} values of $>50 \mu\text{M}$ for the remaining compounds.^{35,36} In a mitochondrial transmembrane potential (MTP) assay, only compounds **3**, **7**, and **8** showed activity, with ED_{50} values of 8.5, 75, and 310 nM , respectively.²⁵ From these data, it can be proposed that the presence of a free hydroxy group at C-6 and a *cis* configuration in the phenylpropanoid moiety of the 5,6-dihydro- α -pyrone compounds are required for activity in this mechanistic assay.

Experimental Section

General Experimental Procedures. Optical rotations were obtained on a Perkin-Elmer 343 automatic polarimeter. UV spectra were measured with a Perkin-Elmer Lambda 10 UV/vis spectrometer. CD spectra were measured on a JASCO J-810 spectrometer. IR spectra were run on a Thermo Scientific Nicolet 6700 FT-IR spectrometer. NMR spectroscopic data were recorded at room temperature on a Bruker Avance DPX-300 or DRX-400 spectrometer. Column chromatography was performed with 65–250 or 230–400 mesh silica gel (Sorbent Technologies, Atlanta, GA). Analytical thin-layer chromatography was conducted on 250 μm thickness Partisil silica gel 60 F_{254} glass plates (Whatman, Clifton, NJ). Analytical and semipreparative HPLC were carried out on a Waters system composed of a 600 controller, a 717 plus autosampler, and a 2487 dual-wavelength absorbance detector, with Waters Sunfire analytical ($4.6 \times 150 \text{ mm}$) and preparative ($19 \times 150 \text{ mm}$) C_{18} columns. All other chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Plant Material. The entire plant of *H. brevipes* were collected from Tawangmangu Village, Karanganyar, Central Java, Indonesia, in February 2003. The plant was identified by Dr. Sugeng Sugiarso, Research Center for Indonesian Medicinal Plants, Ministry of Health, Indonesia. A voucher specimen (accession number P4046) has been deposited at the Field Museum of Natural History, Chicago, Illinois.

Extraction and Isolation. The air-dried whole plants of *H. brevipes* (716 g) were ground and extracted with methanol overnight (3 \times 3 L). The macerate was concentrated *in vacuo* (46.5 g) and partitioned to afford a hexane extract (12.0 g), a chloroform extract (10.3 g), and an aqueous extract (21.9 g). The chloroform extract was fractionated using

silica gel vacuum-liquid chromatography (Aldrich, Si gel 60, 63–200 mesh, 8.5 × 19 cm) using pure hexane initially, followed in turn by a gradient of increasing polarity using hexane–ethyl acetate and ethyl acetate–methanol. The column was then washed with 100% methanol. Altogether, 10 pooled fractions (F06–F15) were collected. Ursolic acid (15 mg) was obtained as a precipitate from F07. A yellow solid precipitated from fraction F08, which was chromatographed further using silica gel (Aldrich, Si gel 60, 230–400 mesh, 3.0 × 52 cm), beginning with 5:1 hexane–acetone, followed by a gradient of increasing polarity, and washed with 100% methanol to afford purified ayanin (30 mg). Daucosterol (11 mg) was obtained as a precipitate from F12.

Fraction F08 (1.03 g) was found to be the most active for the MCF-7 breast cancer cell line (ED₅₀ 6.0 μg/mL) and was fractionated by passage on silica gel (5.0 × 58 cm, 230–400 mesh) using the following solvent systems: 100% CH₂Cl₂ (1.5 L), 2% MeOH–CH₂Cl₂ (1 L); 3% MeOH–CH₂Cl₂ (1 L), 5% MeOH–CH₂Cl₂ (500 mL); 15% MeOH–CH₂Cl₂ (1 L), 50% MeOH–CH₂Cl₂ (1 L), and 100% MeOH (1.5 L), with 11 pooled fractions obtained (F08F1–F08F11). Ombuin (13 mg) was isolated from the mother liquor of F08F5. Maslinic acid (20 mg) was obtained as a precipitate from F08F9. Fraction F09 was partitioned on a Sephadex LH-20 column (4 × 50 cm) using pure MeOH to give three subfractions (F0901–F0903). A mixture (60 mg) obtained from subfraction F0902 (1.2 g) by repeated silica gel chromatography was purified by preparative HPLC to give the new compounds **1** (*t*_R 26.1 min, 34 mg) and **2** (*t*_R 27.7 min, 10 mg), using MeCN–H₂O (28:72, 10 mL/min) as eluting solvent. Fraction F10 (1.27 g) was fractionated using a Sephadex LH-20 column (230–400 mesh, 3.0 × 100 cm) eluted with pure MeOH, and seven pooled fractions (F10F1–F10F7) were obtained. Fraction F10F2 (560 mg) was chromatographed over a fine silica gel column (230–400 mesh, 2.0 × 45 cm) eluted with CHCl₃–acetone from 10:1 to 6:1, to give a mixture (110 mg). The obtained mixture was subjected to preparative HPLC with MeCN–H₂O (30:70, 10 mL/min) as solvent to give **7** (*t*_R 21.2 min, 28 mg), **6** (*t*_R 24.1 min, 7 mg F10F2K2), and **5** (*t*_R 36.3 min, 4 mg). 5,6,3'-Trihydroxy-2,7,4'-trimethoxyflavone (**8**, 108 mg) was purified from F10F4 by repeated silica gel column chromatography (230–400 mesh, 4 × 50 cm) eluted with CHCl₃–MeOH (from 10:1 to 5:1). Fractions F12 and F13 were combined, and the new bulked fraction F12' (1.8 g) was chromatographed over a Sephadex LH-20 column (4.5 × 50 cm) using pure MeOH as eluting solvent to give five subfractions (F12'F1–F12'F5). Subfraction F12'F4 (460 mg) was passed over a silica gel column (230–400 mesh, 1 × 40 cm), eluted with CHCl₃–acetone (4:1), to give a mixture (60 mg). This mixture was separated by preparative HPLC, using MeCN–0.5% formic acid water solution (25:75, 10 mL/min) as solvent system, to afford the new compounds **3** (*t*_R 21.8 min, 42 mg) and **4** (*t*_R 23.2 min, 11 mg).

Brevipolide A (1): colorless gum; [α]_D²⁰ +6.3 (*c* 0.2, MeOH); CD (*c* 1.1 × 10⁻⁵ M, MeOH) λ_{max} (Δε) 232 (–0.75), 259.5 (+2.27), 279 (+0.95), 300 (+2.14) nm; UV (MeOH) λ_{max} (log ε) 208 (0.93), 316 (0.90) nm; IR (film) ν_{max} 3355 (br), 3018, 2938, 1703, 1623, 1605, 1582, 1514, 1438, 1370, 1229, 1165, 1066, 1039, 816, 752 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) data, see Table 1; ¹³C NMR (100 MHz, CDCl₃) data, see Table 2; HRESIMS *m/z* 451.1354 [M + Na]⁺ (calcd for C₂₃H₂₄O₈Na, 451.1369).

Brevipolide B (2): colorless gum; [α]_D²⁰ +3.7 (*c* 0.2, MeOH); CD (*c* 1.1 × 10⁻⁵ M, MeOH) λ_{max} (Δε) 230 (–0.86), 160 (+2.82), 280 (+1.02), 300 (+0.55) nm; UV (MeOH) λ_{max} (log ε) 213 (1.23), 315 (1.18) nm; IR (film) ν_{max} 3360 (br), 3015, 2933, 1704, 1605, 1512, 1446, 1372, 1234, 1160, 1046, 817, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) data, see Table 1; ¹³C NMR (100 MHz, CDCl₃) data, see Table 2; HRESIMS *m/z* 451.1343 [M + Na]⁺ (calcd for C₂₃H₂₄O₈Na, 451.1369).

Brevipolide C (3): colorless gum; [α]_D²⁰ +9.4 (*c* 0.1, MeOH); CD (*c* 1.2 × 10⁻⁵ M, MeOH) λ_{max} (Δε) 228 (–1.00), 261 (+3.6), 280 (+2.40), 300 (+3.41) nm; UV (MeOH) λ_{max} (log ε) 208 (1.17), 252 (1.00) nm; IR (film) ν_{max} 3408 (br), 3018, 2919, 1703, 1631, 1600, 1517, 1445, 1385, 1263, 1161, 1074, 812, 756 cm⁻¹; ¹H NMR (400 MHz, acetone-*d*₆) data, see Table 1; ¹³C NMR (100 MHz, acetone-*d*₆) data, see Table 2; HRESIMS *m/z* 425.1216 [M + Na]⁺ (calcd for C₂₁H₂₂O₈Na, 425.1212).

Brevipolide D (4): colorless gum; [α]_D²⁰ +8.3 (*c* 0.1, MeOH); UV (MeOH) λ_{max} (log ε) 208 (0.97), 333 (0.77) nm; CD (*c* 1.2 × 10⁻⁵ M, MeOH) λ_{max} (Δε) 229 (–1.11), 261 (+2.46), 279 (+1.10), 301 (+2.15) nm; IR (film) ν_{max} 3410 (br), 2953, 2927, 1722, 1703, 1631, 1604,

Table 2. ¹³C NMR Chemical Shifts of **1–6**

position	1 ^a	2 ^a	3 ^b	4 ^b	5 ^c	6 ^b
1	163.7	163.9	164.4	164.2	166.0	164.1
2	121.0	121.1	121.5	121.2	121.4	121.2
3	145.1	145.1	147.4	147.3	148.0 ^d	147.1
4	24.3	24.6	25.2	24.9	25.7	24.8
5	77.9	78.1	81.8	81.5	79.8	81.6
6	74.5	74.5	72.1	71.6	76.0	71.6
7	25.2	25.2	28.0	27.6	26.6	27.7
8	14.4	14.7	14.5	14.3	15.1	14.2
9	22.5	22.6	21.4	21.0	23.5	21.1
10	207.3	207.3	207.3	207.1	208.9	207.1
11	75.0	75.0	76.1	75.9	76.6	75.8
12	15.9	15.8	16.8	16.4	16.4	16.4
1'	126.1	126.8	127.8	127.8	127.7	131.1
2'	130.1	132.3	115.6	115.6	115.3	133.9
3'	116.0	115.1	149.3	148.4	150.0	115.7
4'	158.9	157.6	146.6	145.1	147.0	159.9
5'	116.0	115.1	116.7	118.5	116.7	115.7
6'	130.1	132.3	123.1	125.7	123.3	133.9
7'	146.0	145.2	147.0	145.9	148.1 ^d	145.6
8'	113.6	115.6	115.1	115.5	114.4	115.7
9'	168.8	165.9	167.2	166.2	168.5	166.3
OCCH ₃	170.5	170.6			172.1	
OC ₂ H ₅	20.9	20.9			21.0	

^a In CDCl₃, ^b In acetone-*d*₆, ^c In CD₃OD. ^d Data interchangeable.

1517, 1445, 1389, 1263 1165, 820, 756 cm⁻¹; ¹H NMR (400 MHz, acetone-*d*₆) data, see Table 1; ¹³C NMR (100 MHz, acetone-*d*₆) data, see Table 2; HRESIMS *m/z* 425.1187 [M + Na]⁺ (calcd for C₂₁H₂₂O₈Na, 425.1212).

Brevipolide E (5): colorless gum; [α]_D²⁰ +10.0 (*c* 0.1, MeOH); UV (MeOH) λ_{max} (log ε) 208 (1.22), 333 (1.07) nm; CD (*c* 1.1 × 10⁻⁵ M, MeOH) λ_{max} (Δε) 230 (–0.95), 260 (+2.74), 280 (+0.99), 300 (+2.53) nm; IR (film) ν_{max} 3390 (br), 3018, 2919, 2843, 1714, 1631, 1597, 1514, 1442, 1245, 1157, 816, 756 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) data, see Table 1; ¹³C NMR (100 MHz, CD₃OD) data, see Table 2; HRESIMS *m/z* 467.1293 [M + Na]⁺ (calcd for C₂₃H₂₄O₉Na, 467.1318).

Brevipolide F (6): colorless gum; [α]_D²⁰ +7.0 (*c* 0.2, MeOH); CD (*c* 1.2 × 10⁻⁵ M, MeOH) λ_{max} (Δε) 231 (–0.83), 261 (+1.94), 282 (+0.88), 301 (+1.83) nm; UV (MeOH) λ_{max} (log ε) 210 (1.08), 316 (1.22) nm; IR (film) ν_{max} 3397 (br), 3010, 2930, 1703, 1605, 1514, 1438, 1385, 1264, 1169, 1070, 1036, 816, 756 cm⁻¹; ¹H NMR (400 MHz, acetone-*d*₆) data, see Table 1; ¹³C NMR (100 MHz, acetone-*d*₆) data, see Table 2; HRESIMS *m/z* 409.1263 [M + Na]⁺ (calcd for C₂₁H₂₂O₇Na, 409.1263).

Preparation of R- and S-MTPA Ester Derivatives of 3. Compound **3** (1.5 mg) was added to two separate NMR tubes and was dried under a vacuum overnight. Deuterated pyridine (0.4 mL) was transferred to each tube under N₂ flow, followed by injection of (*S*)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) chloride (5 μL) or (*R*)-MTPA chloride (5 μL) to give the (*R*)-MTPA ester and the (*S*)-MTPA ester of **3**, respectively. The tubes were stored overnight at room temperature to allow completion of reactions before NMR measurements.

R-MTPA Ester of 3: δ 6.75 (1H, m, H-3), 6.06 (1H, d, *J* = 9.9 Hz, H-2), 5.55 (1H, q, *J* = 7.0 Hz, H-11), 5.38 (1H, dd, *J* = 9.7, 2.7 Hz, H-6), 4.82 (1H, m, H-5), 2.77 (1H, m, H-9), 2.32 (2H, m, H-4), 2.13 (1H, m, H-7), 1.56 (3H, d, *J* = 7.0 Hz, H-12), 1.47 (1H, m, H-8), 1.45 (1H, m, H-8).

S-MTPA Ester of 3: δ 6.86 (1H, m, H-3), 6.12 (1H, dd, *J* = 9.7, 1.2 Hz, H-2), 5.51 (1H, q, *J* = 7.1 Hz, H-11), 5.39 (1H, dd, *J* = 8.8, 2.3 Hz, H-6), 4.93 (1H, dt, *J* = 12.0, 2.5, 2.5 Hz, H-5), 2.74 (1H, m, H-9), 2.52 (2H, m, H-4), 2.02 (1H, m, H-7), 1.56 (3H, d, *J* = 7.1 Hz, H-12), 1.41 (1H, m, H-8), 1.34 (1H, m, H-8).

Cytotoxicity Assay. Cytotoxicity assays on extracts, chromatographic fractions, and isolated compounds from *H. brevipus* were tested against MCF-7 human breast cancer cells, HT-29 human colon cancer cells, and Lu1 human lung cancer cells, using an established protocol.³²

Proteasome Fraction Preparation and Proteasome Inhibition Assay. A proteasome fraction was prepared from the HL-60 human leukemic cell line as described previously.^{33,34} The assay buffer (50 mM Tris, pH 7.5, 25 mM KCl, 10 mM NaCl, 1 mM MgCl₂, 0.03% SDS) was added to blank and control wells. Dilutions of the tested compounds were prepared in assay buffer and added to the appropriate wells. The enriched proteasome fraction was diluted to a final assay

concentration of 4 $\mu\text{g/mL}$ using assay buffer, and this dilution was then added to each well. The microtiter plates were then preincubated for 10 min at 37 $^{\circ}\text{C}$ to facilitate inhibitor–enzyme interactions. The enzyme reaction was initiated by adding substrate [*N*-succinyl-Leu-Leu-Val-Tyr-AMC (7-amino-4-methylcoumarin); abbreviated Suc-LLVY-AMC] to a final concentration of 75 μM , and fluorescence measurements commenced immediately. The chymotrypsin-like proteasome activity was determined by measuring the generation of free AMC using an excitation at a wavelength of 360 nm and detection of emitted light at 460 nm. The Suc-LLVY-AMC substrate was obtained from Biomol International (Plymouth Meeting, PA). The proteasome inhibitor bortezomib was used as positive control with an ED_{50} value of 2.5 nM.

Enzyme-Based ELISA NF- κ B Assay. The NF- κ B assay was carried out according to an established protocol.^{35,36} In brief, a nuclear extract was prepared from HeLa cells purchased from the American Type Culture Collection. An EZ-Detect Transcription Factor Assay System ELISA kit (Pierce Biotechnology, Rockford, IL) was used to assess the specific binding ability of activated NF- κ B to the biotinylated-consensus sequence under the presence of tested compounds. The activity of the p50 subunit of NF- κ B was measured by detecting the chemiluminescent signal in a Fluostar Optima plate reader (BMG Labtech Inc., Durham, NC). Rocaglamide was used as a positive control with an ED_{50} value of 2.0 μM in this assay.

Mitochondria Transmembrane Potential Assay (MTP Assay). Changes on the mitochondria transmembrane potential were detected and quantified by a fluorescence cell-based assay. In brief, HT-29 cells cultured in black 96-well plates or black clear-bottom 96-well plates at a density of 6×10^4 were incubated overnight at 37 $^{\circ}\text{C}$ in a CO_2 incubator. Cells were then treated with the test compounds or staurosporine (positive control, ED_{50} 2.6 nM) for 2 h. Immediately afterward, cells were incubated with the lipophilic cationic dye 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanide (JC-1) (Cayman Chemical Company, Ann Arbor, MI) for 30 min. After incubation, cells were washed with a wash buffer to remove unbound staining reagent. The clear-bottom plates were then scanned with a fluorescent imaging microscope (Axiovert 40 CFL, Carl Zeiss Microimaging, Inc., Thornwood, NY). Black 96-well plates were analyzed by a FLUOstar Optima fluorescence plate reader (BMG Labtech, Inc.) with an excitation wavelength of 485 nm and emission wavelength of 530 nm for JC-1 monomers and an excitation wavelength of 560 nm and emission wavelength of 595 nm for J-aggregates. Measurements were performed in duplicate and are representative of at least two independent experiments.²⁵

Acknowledgment. This study was supported by grants U19 CA52956 and P01 CA125066 (P.I., A.D.K.) and P01 CA48112 (P.I., J.M.P.) from NCI, NIH. This research was also supported by Raymond W. Daskotch Graduate Fellowship Fund in Medicinal Chemistry and Pharmacognosy from The Ohio State University (to Y.D.) and a Dean's Scholar Award and University Fellowship from the University of Illinois at Chicago (to M.J.B.). We thank Mr. J. Fowble, College of Pharmacy, The Ohio State University, for facilitating the acquisition of the 300 and 400 MHz NMR spectra. We are grateful to the Mass Spectrometry and Proteomics Facility of the OSU CCIC, for the mass spectra.

Supporting Information Available: ^1H and ^{13}C NMR spectra of compounds **1**–**6**, DEPT and 2D NMR spectra including ^1H – ^1H COSY, HSQC, HMBC, and NOESY of compound **1**, as well as ^1H NMR spectra of *R*- and *S*-MTPA esters of compound **3**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- Fragoso-Serrano, M.; Gonzalez-Chimeo, E.; Pereda-Miranda, R. *J. Nat. Prod.* **1999**, *62*, 45–50.
- Ohsaki, A.; Kishimoto, Y.; Isobe, T.; Fukuyama, Y. *Chem. Pharm. Bull.* **2005**, *53*, 1577–1579.
- Pereda-Miranda, R.; Delgado, G. *J. Nat. Prod.* **1990**, *53*, 182–185.
- Novelo, M.; Cruz, J. G.; Hernandez, L.; Pereda-Miranda, R.; Chai, H.; Mar, W.; Pezzuto, J. M. *J. Nat. Prod.* **1993**, *56*, 1728–1736.
- Kuhnt, M.; Rimpler, H.; Heinrich, M. *Phytochemistry* **1994**, *36*, 485–489.
- Pereda-Miranda, R.; Hernandez, L.; Villavicencio, M. J.; Novelo, M.; Ibarra, P.; Chai, H.; Pezzuto, J. M. *J. Nat. Prod.* **1993**, *56*, 583–593.
- Boalino, D. M.; Connolly, J. D.; McLean, S.; Reynolds, W. F.; Tinto, W. F. *Phytochemistry* **2003**, *64*, 1303–1307.
- Gupta, M. P.; Monge, A.; Karikas, G. A.; Lopez de Cerain, A.; Solis, P. N.; de Leon, E.; Trujillo, M.; Suarez, O.; Wilson, F.; Montenegro, G.; Noriega, Y.; Santana, A. I.; Correa, M.; Sanchez, C. *Int. J. Pharmacogn.* **1996**, *34*, 19–27.
- Goun, E.; Cunningham, G.; Chu, D.; Nguyen, C.; Miles, D. *Fitoterapia* **2003**, *76*, 592–596.
- Kinghorn, A. D.; Farnsworth, N. R.; Soejarto, D. D.; Cordell, G. A.; Swanson, S. M.; Pezzuto, J. M.; Wani, M. C.; Wall, M. E.; Oberlies, N. H.; Kroll, D. J.; Kramer, R. A.; Rose, W. C.; Vite, G. D.; Fairchild, C. R.; Peterson, R. W.; Wild, R. *Pharm. Biol.* **2003**, *41* (Suppl.), 53–67.
- Kinghorn, A. D.; Carcache-Blanco, E. J.; Chai, H.-B.; Orjala, J.; Farnsworth, N. R.; Soejarto, D. D.; Oberlies, N. H.; Wani, M. C.; Kroll, D. J.; Pearce, C. J.; Swanson, S. M.; Kramer, R. A.; Rose, W. C.; Emanuel, S.; Vite, G. D.; Jarjoura, D.; Cope, F. O. *Pure Appl. Chem.* **2009**, *81*, 1051–1063.
- Hegde, V. R.; Pu, H.; Patel, M.; Das, P. R.; Strizki, J.; Gullo, V. P.; Chou, C.-C.; Buevich, A. V.; Chan, T.-M. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5339–5342.
- Faizi, S.; Ali, M.; Saleem, R.; Irfanullah; Bibi, S. *Magn. Reson. Chem.* **2001**, *39*, 399–405.
- Mahato, S. B.; Pundu, A. P. *Phytochemistry* **1994**, *37*, 1517–1575.
- Matsuda, H.; Morikawa, T.; Toguchida, I.; Yoshikawa, M. *Chem. Pharm. Bull.* **2002**, *50*, 788–795.
- Skibinski, A.; Merfort, I.; Willuhn, G. *Phytochemistry* **1994**, *37*, 1635–1636.
- Priest, H. A.; Bonafede, J. D.; Ruveda, E. *Phytochemistry* **1977**, *16*, 1579–1582.
- Adams, J. *Drug Discovery Today* **2003**, *8*, 307–315.
- Zavrski, I.; Kleeberg, L.; Kaiser, M.; Fleissner, C.; Heider, U.; Sterz, J.; Jakob, C.; Sezer, O. *Curr. Pharm. Des.* **2007**, *13*, 471–485.
- Gilmore, T.; Gapuzan, M.-E.; Kalaitzidis, D.; Starczynowski, D. *Cancer Lett.* **2002**, *181*, 1–9.
- Andela, V. B. *Curr. Cancer Drug Targets* **2004**, *4*, 337–344.
- Basseres, D. S.; Baldwin, A. S. *Oncogene* **2006**, *25*, 6817–6830.
- Fesik, S. W. *Nat. Rev. Cancer* **2005**, *5*, 876–885.
- Fulda, S. *Int. J. Cancer* **2009**, *124*, 511–515.
- Salvioli, S.; Ardizzoni, A.; Franceschi, C.; Cossarizza, A. *FEBS Lett.* **1997**, *411*, 77–82.
- Wilberg, K. B.; Barth, D. E.; Schertler, P. H. *J. Org. Chem.* **1973**, *38*, 378–381.
- Davies-Coleman, M. T.; Rivett, D. E. A. *Phytochemistry* **1987**, *26*, 3047–3050.
- Dale, J. A.; Mosher, H. S. *J. Am. Chem. Soc.* **1973**, *95*, 512–519.
- Sullivan, G. R.; Dale, J. A.; Mosher, H. S. *J. Org. Chem.* **1973**, *38*, 2143–2147.
- Seco, J. M.; Quinoa, E.; Riguera, R. *Chem. Rev.* **2004**, *104*, 17–117.
- Su, B.-N.; Park, E. J.; Mbwambo, Z. H.; Santarsiero, B. D.; Mesecar, A. D.; Fong, H. H. S.; Pezzuto, J. M.; Kinghorn, A. D. *J. Nat. Prod.* **2002**, *65*, 1278–1282.
- Seo, E.-K.; Kim, N.-C.; Mi, Q.; Chai, H.; Wall, M. E.; Wani, M. C.; Navarro, H. A.; Burgess, J. P.; Graham, J. G.; Cabieses, F.; Tan, G. T.; Farnsworth, N. R.; Pezzuto, J. M.; Kinghorn, A. D. *J. Nat. Prod.* **2001**, *64*, 1483–1485.
- Vinitsky, A.; Anton, L. C.; Snyder, H. L.; Orłowski, M.; Bennink, J. R.; Yewdell, J. W. *J. Immunol.* **1997**, *159*, 554–564.
- Su, B.-N.; Hwang, B. Y.; Chai, H.-B.; Carcache-Blanco, E. J.; Kardono, L. B. S.; Afriastini, J. J.; Riswan, S.; Wild, R.; Laing, N.; Farnsworth, N. R.; Cordell, G. A.; Swanson, S. M.; Kinghorn, A. D. *J. Nat. Prod.* **2004**, *67*, 1911–1914.
- Renard, P.; Ernest, I.; Houbion, A.; Art, M.; Le Calvez, H.; Raes, M.; Remacle, J. *Nucleic Acids Res.* **2001**, *29*, e21.
- Salim, A. A.; Pawlus, A. D.; Chai, H.-B.; Farnsworth, N. R.; Kinghorn, A. D.; Carcache-Blanco, E. J. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 109–112.

NP9001724